‍‍‍‍Chemotherapy in epithelial ovarian cancer. Dr.Azarm.

Slides:



Advertisements
Similar presentations
Treatment.
Advertisements

Advances and Emerging Therapy for Lung Cancer
“Taking Care of Tomorrows Patient Better than Today”… the Future is Now Set A1 – Title Slide David O’Malley, M.D.
Gynecologic Oncology Group Gynecologic Oncology Group Uterine Corpus Trials: GCIG David Scott Miller, M.D., F.A.C.O.G., F.A.C.S. Director and Dallas Foundation.
Intraperitoneal therapy in ovarian cancer Edward L. Trimble, MD, MPH National Cancer Institute, USA.
Neoadjuvant Chemotherapy in Locally Advanced Squamous Cell Cancer of Head and Neck Mei Tang, MD.
O VARIAN C ANCER C LINICAL T RIALS P LANNING M EETING Unanswered Questions in Upfront Therapy IP Therapy Issue Keiichi Fujiwara, MD, PhD Saitama Medical.
CHEMOTHERAPY AND BLADDER CANCER Walter Stadler, MD, FACP University of Chicago.
Randomized Phase III Trials of Intravenous vs. Intraperitoneal Therapy in Optimal Ovarian Cancer Deborah K. Armstrong, M.D. Associate Professor of Oncology,
Adjuvant therapy for renal cell carcinoma Dr.Mina Tajvidi oncologist.
Neoadjuvant Chemotherapy in Ovarian Cancer Key issues in trial design.
Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.
Evidence Based Decision Making In Gynecologic Cancer Paolo Zola Turin, ITALY Adriana Bermudez Buenos Aires, ARGENTINA.
A Meta Analysis of Risk of Cardiovascular Events in Patients with Metastatic Breast Cancer (MBC) Treated with Anti Vascular Endothelial Growth Factor (VEGF)
Drug Treatment of Metastatic Breast Cancer
Ovarian Cancer May 2007 Dr Anna Winship Guy’s & St. Thomas’ NHS Trust Click Here For First Question Oncology Registrars’ Forum “Best of Five”
EN.8 - A PHASE III STUDY OF STANDARD THERAPY VERSUS RIDAFOROLIMUS IN WOMEN WITH RECURRENT OR METASTATIC ENDOMETRIAL CANCER WHO HAVE PREVIOUS HAD CHEMOTHERAPY.
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer 부산백병원 산부인과 R2 서영진.
Clinical features and outcome in ovarian sarcomas: Analysis of a single-institution experience A López Pousa, X Gonzàlez Farré, MJ. Quintana, S Bagué,
4% of all female cancers 25% of all gynecologic cancers life time risk: 1/70 ¾ advanced stage most lethal Epithelial Ovarian Cancer:
Patterns of Care in Medical Oncology Neoadjuvant and Adjuvant Treatment of Rectal Cancer.
Sequential vs. concurrent chemoradiotherapy for locally advanced non-small cell carcinoma.
1 Phase II trial of sequential gemcitabine and carboplatin followed by paclitaxel as first-line treatment of advanced urothelial carcinoma Presented by.
10 Minutes Talk 吳 華 席 Hua-Hsi Wu, MD OB/GYN, VGH-TPE Sep 08, 2008.
Thymidine phosphorylase (TP) upregulation Dose- and time-dependent upregulation of TP in human colon cancer xenografts PaclitaxelDocetaxel.
ESMO 2011 Lung Cancer AVAPERL Study Authors: Dr. Sunil Verma Date posted: September 28 th, 2011.
Recent Advances in Head and Neck Cancer Robert I. Haddad, M.D., and Dong M. Shin, M.D. The NEW ENGLAND JOURNAL of MEDICINE N Engl J Med 2008;359:
Result of Interim Analysis of Overall Survival in the GCIG ICON7 Phase III Randomized Trial of Bevacizumab in Women with Newly Diagnosed Ovarian Cancer.
1 SNDA Gemzar plus Carboplatin Treatment of Late Relapsing Ovarian Cancer.
Herceptin ® : leading the way in metastatic breast cancer care Steffen Kahlert.
ESMO 2011 Breast Cancer Trastuzumab in untreated MBC Authors: CARE Faculty (Drs. Anil Joy and Sunil Verma) Date posted: October.
Clique para editar o título mestre. Incorporation of bevacizumab in first-line treatment of advanced ovarian cancer: results and indications Ursula Matulonis,
NSCLC stage IIIA type of chemotherapy ? Swiss tumor board Bern – Dr. Christian Monnerat Département Pluridisciplaire d’Oncologie – Hôpital Neuchâtelois.
Treatment for metastatic bladdercancer (chemotherapy&radiotherapy) Dr.Mina Tajvidi oncologist.
1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.
GOG0172: The Dings The recommended regimen is not feasible –Substitution of carboplatin for cisplatin –Reduce cisplatin from 100 mg/m 2 to 75 mg/m 2 –Change.
GCIG Rare Tumor Working Group Chicago, IL, June 3, 2010 Chair: Isabelle Ray-Coquard Co-Chair: David M. Gershenson.
OCEANS: A Randomized, Double- Blinded, Placebo-Controlled Phase III Trial of Chemotherapy with or without Bevacizumab (BEV) in Patients with Platinum-
Taxanes — Taxanes are among the most active agents for metastatic breast cancer – Docetaxel, Paclitaxel, NabPaclitaxel. Anthracyclines – Doxorubicin, Epirubicin,
TAXOL® (paclitaxel) for Adjuvant Treatment of Node Positive Breast Cancer Oncologic Drugs Advisory Committee TAXOL® (paclitaxel) for Adjuvant Treatment.
Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.
Lenalidomide Maintenance After Stem-Cell Transplantation for Multiple Myeloma: Follow-Up Analysis of the IFM Trial Attal M et al. Proc ASH 2013;Abstract.
Agency Review of sNDA SE-006 DOXIL for Ovarian Cancer Division of Oncology Drug Products Office of Drug Evaluation 1 Center for Drug Evaluation.
Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.
INTERGROUP STUDY 0148 BMS CA Effect of TAXOL® (paclitaxel) and Doxorubicin Dose on Disease Free and Overall Survival of Patients with Node Positive.
Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.
Results of a Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic HER2-Negative Breast.
Adjuvant and Neoadjuvant Therapy in Non- Small Cell Lung Cancer Seminars in Oncology 2oo5;32 (suppl 2):S9-S15 Kyung Hee Medical Center Department of Thoracic.
Relapsed/Refractory Ovarian Cancer: Decision Points in Diagnosis and New Treatment Strategies Friday, March 24, 2006 Palm Springs Convention Center Primrose.
Daunorubicin VS Mitoxantrone VS Idarubicin As Induction and Consolidation Chemotherapy for Adults with Acute Myeloid Leukemia : The EORTC and GIMEMA Groups.
GCIG Rare Tumor Working Group Prague, CZ, October, 2010 Chair: Isabelle Ray-Coquard Co-Chair: David M. Gershenson.
Empowering induction therapy for locally advanced head and neck cancer A. Argiris1* & M. V. Karamouzis2 1Division of Hematology–Oncology, Department of.
Esophageal Cancer: A Critical Evaluation of Systemic Second-Line Therapy Christiane Maria Rosina Thallinger, Markus Raderer, and Michael Hejna J Clin Oncol.
Neoadjuvant chemotherapy in the treatment of NSCLC Department of Thoracic Oncology, University Hospital Ghent, Belgium Current Opinion in Oncology 2007,
ADJUVANT CAPECITABINE AND OXALIPLATIN FOR GASTRIC CANCER AFTER D2 GASTRECTOMY (CLASSIC): A PHASE 3 OPEN-LABEL,RANDOMISED CONTROLLED TRIAL Yung-Jue Bang*,
Case report Ovarian cancer Ami Fishman, M.D. Meir Hospital - Sapir Med Center Kfar-Saba, Israel Ovarian cancer Ami Fishman, M.D. Meir Hospital.
RANDOMIZED PHASE II STUDY OF NABPACLITAXEL, IN RECURRENT ADVANCED OR METASTATIC CERVICAL CANCER MITO CER-NAB Enrica Mazzoni, MD Medical Oncology & Breast.
Management of Malignant Ovarian Germ Cell Tumors
Adjuvant chemotherapy for early stage epithelial ovarian cancer
Dose dense chemotherapy in the adjuvant treatment of ovarian cancer
Belani CP et al. ASCO 2009; Abstract CRA8000. (Oral Presentation)
Management of metastatic and recurrent head and neck cancer
Palumbo A et al. Proc ASH 2012;Abstract 200.
Figure #1 Overall survival Figure #2 Disease free survival
PHASE I/II STUDY OF PEGYLATED LIPOSOMAL DOXORUCIN (PLD) AND GEMCITABINE (GEM) IN RECURRENT PLATIN RESISTANT OVARIAN CANCER (OC). A Study of the VWOG.
OPTIMIZING TREATMENT FOR ADVANCED OVARIAN CANCER:
بنام خداوند جان و خرد.
Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer:
Nab-paclitaxel in Ovarian Cancer
Gordon LI et al. Proc ASH 2010;Abstract 415.
Presentation transcript:

‍‍‍‍Chemotherapy in epithelial ovarian cancer. Dr.Azarm

Recommendation — platinum agents (especially carboplatin) plus paclitaxel, carboplatin plus paclitaxel is the standard of care for EOC The regimen I use is paclitaxel 175 mg/m2 over three hours plus carboplatin AUC 6 to 7.5 (starting with the higher dose), every three weeks for sixcarboplatinpaclitaxel

Taxanes plus platinum agents: The regimen of paclitaxel (135 mg/m2 over 24 hours) immediately followed by cisplatin (75 mg/m2) offers the best therapeutic ratio, and initial studies ameliorated concerns for overlapping neurotoxicitycisplatin Dr.Azarm

Carboplatin plus docetaxel: Docetaxel may represent Docetaxel a less toxic alternative to paclitaxel. paclitaxel Dr.Azarm

Recommendation : Based upon the favorable safety profile of platinum agents (especially carboplatin) plus paclitaxel.carboplatinpaclitaxel The regimen doses are paclitaxel 175 mg/m2 over three hours plus carboplatin AUC 6 to 7.5 (starting with the higher dose), every three weeks for six cycles. For women with advanced disease (stage III and IV with either small volume of large volume disease), response rates approach 90 percent, with 75 percent achieving a clinical complete response.

Maintenance therapy : -Focused upon extending the duration of induction chemotherapy -Prolonged administration of single agents ‍Chemotherapy -IP chemotherapy, -Hormonal agents, -Immunotherapy. None of these strategies has been shown to improve outcomes

Intraperitoneal chemotherapy : IP therapy can permit a several-fold increase in drug concentration in the abdominal cavity compared to systemic administration. IP cisplatin IP paclitaxel IP chemotherapy is benefit in a subset of women with optimally cytoreduced EOC (to <0.5 cm), IP chemotherapy should not be considered standard therapy, and used only in the context of a clinical trial.

Stem cell-supported high dose chemotherapy - Response rates are initially high, but short lived (usually six to nine months) - There is no convincing evidence of a long-term survival benefit - Women undergoing transplant with platinum- resistant bulky disease do particularly poorly prognosis.

NEOADJUVANT CHEMOTHERAPY VERSUS INITIAL SURGICAL DEBULKING: Primary surgical cytoreduction followed by systemic chemotherapy is the preferred initial management for women with stage III or IV EOC.

CONCLUSIONS AND RECOMMENDATIONS : The combination of a platinum (usually carboplatin) and paclitaxel is standard therapy for the first-line treatment of women with EOC who require systemic chemotherapy. carboplatin For women with advanced disease (stage III and IV with either small volume of large volume disease), response rates approach 90 percent, with 75 percent achieving a clinical complete response.

Treatment of germ cell tumors of the ovary

All women with nondysgerminomatous germ cell malignancies, except those with unruptured stage IA disease, grade 1 immature teratomas should receive postoperative adjuvant chemotherapy.

Patients with stage II or III disease )GST) who have a complete tumor resection and adjuvant chemotherapy will almost always remain free of recurrence.

VAC (vincristine, actinomycin-D, and cyclophosphamide)vincristinecyclophosphamide PVB (cisplatin, vinblastine, and bleomycin)cisplatinvinblastinebleomycin both had good activity against the various germ cell malignancies. Choice of regimen in GST of Ovary :

Management of immature teratomas Several reports support the successful management of these patients with surgery alone.

MANAGEMENT OF ADVANCED DISEASE Patients with incompletely resected metastatic ovarian GCTs should receive cisplatin-based combination chemotherapy.

PEB cisplatin 20 mg/m2 days one through 5 days, etoposide 100 mg/m2 days one through five, cisplatin both every 21 days, bleomycin 30 units weekly) bleomycin for three to four courses has become the standard regimen for patients with advanced ovarian GCT, and long- term survival can be expected in 60 to 80 percent of cases.

Etoposide (120 mg/m2 on days 1 through 3), ‍‍‍‍Carboplatin (600 mg/m2 on day 2), and Bleomycinleomycin (15 mg/m2 on day 3 ), with courses administered every 3 to 4 weeks until remission, and then two more courses. With a median follow-up of 53 months, the five-year survival and event-free survival rates were 91 and 88 percent,

Cisplatin-based chemotherapy is highly effective for advanced (incompletely resected or recurrent) dysgerminoma ysgerminoma: d

LATE EFFECTS OF TREATMENT : -renal and gonadal dysfunction, -neurotoxicity, -cardiovascular toxicity, and -secondary malignancies